Excess costs of comorbidities in chronic obstructive pulmonary disease: A systematic review

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Huber, Manuel B ^a   Wacker, Margarethe E ^a   Vogelmeier, Claus F ^b   Leidl, Reiner ^a,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONGESTIVE HEART FAILURE; COST OF ILLNESS; DIABETES MELLITUS; HEALTH CARE COST; HOSPITAL PATIENT; HUMAN; HYPERTENSION; KIDNEY DISEASE; LIVER DISEASE; OUTPATIENT CARE; PATIENT CARE; PEPTIC ULCER; PNEUMONIA; PREVALENCE; SLEEP DISORDERED BREATHING; SYSTEMATIC REVIEW; FEMALE; MALE; META ANALYSIS; MORTALITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTOR;

COMORBIDITY; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MORTALITY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS;

EID: 84929454280     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123292     Document Type: Article

References (83)

1. WHO. The Top 10 Causes of Death. 2014 [November 2014]; Available: http://www.who.int/mediacentre/factsheets/fs310/en/.
2. Barnes PJ. Immunology of Asthma and Chronic Obstructive Pulmonary Disease. Nat Rev Immunol. 2008 Mar; 8(3):183-92. doi: 10.1038/nri2254 PMID: 18274560
3. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, Inflammation and Co-Morbidity - a Common Inflammatory Phenotype? Respir Res. 2006; 7:70. PMID: 16669999
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: Gold Executive Summary. Am J Respir Crit Care Med. 2007 Sep 15; 176(6):532-55. PMID: 17507545
5. Raherison C, Girodet PO. Epidemiology of Copd. Eur Respir Rev. 2009 Dec; 18(114):213-21. doi: 10.1183/09059180.00003609 PMID: 20956146
6. Shaykhiev R, Otaki F, Bonsu P, Dang DT, Teater M, Strulovici-Barel Y, et al. Cigarette Smoking Reprograms Apical Junctional Complex Molecular Architecture in the Human Airway Epithelium in Vivo. Cell Mol Life Sci. 2011 Mar; 68(5):877-92. doi: 10.1007/s00018-010-0500-x PMID: 20820852
7. Keely S, Talley NJ, Hansbro PM. Pulmonary-Intestinal Cross-Talk in Mucosal Inflammatory Disease. Mucosal Immunol. 2012 01//print; 5(1):7-18. doi: 10.1038/mi.2011.55 PMID: 22089028
8. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in Lung Function and Morbidity from Chronic Obstructive Pulmonary Disease in Alpha1-Antitrypsin Mz Heterozygotes: A Longitudinal Study of the General Population. Ann Intern Med. 2002 Feb 19; 136(4):270-9. PMID: 11848724
9. Garcia-Nunez M, Millares L, Pomares X, Ferrari R, Perez-Brocal V, Gallego M, et al. Severity-Related Changes of Bronchial Microbiome in Copd. J Clin Microbiol. 2014 Sep 24.
10. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway Microbiome Dynamics in Exacerbations of Chronic Obstructive Pulmonary Disease. J Clin Microbiol. 2014 Aug; 52(8):2813-23. doi: 10.1128/JCM.00035-14 PMID: 24850358
11. Sze MA, Hogg JC, Sin DD. Bacterial Microbiome of Lungs in Copd. Int J Chron Obstruct Pulmon Dis. 2014; 9:229-38. doi: 10.2147/COPD.S38932 PMID: 24591822
12. Aydemir Y, Aydemir O, Kalem F. Relationship between the Gold Combined Copd Assessment Staging System and Bacterial Isolation. Int J Chron Obstruct Pulmon Dis. 2014; 9:1045-51. doi: 10.2147/COPD.S70620 PMID: 25298733
13. Park H, Shin JW, Park SG, Kim W. Microbial Communities in the Upper Respiratory Tract of Patients with Asthma and Chronic Obstructive Pulmonary Disease. PLoS One. 2014; 9(10):e109710. doi: 10.1371/journal.pone.0109710 PMID: 25329665
14. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and Burden of Copd: A Population Based Case-Control Study. PLoS ONE. 2013 17 May; 8(5).
15. Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012 Jul 15; 186(2):155-61. doi: 10.1164/rccm.201201-0034OC PMID: 22561964
16. Decramer M, Janssens W. Chronic Obstructive Pulmonary Disease and Comorbidities. Lancet Respir Med. 2013 Mar; 1(1):73-83. doi: 10.1016/S2213-2600(12)70060-7 PMID: 24321806
17. Capobianco E, Lio P. Comorbidity: A Multidimensional Approach. Trends Mol Med. 2013 Sep; 19 (9):515-21. doi: 10.1016/j.molmed.2013.07.004 PMID: 23948386
18. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in Copd: Role of Comorbidities. European Respiratory Journal. 2006 December; 28(6):1245-57. PMID: 17138679
19. Maclay JD, McAllister DA, Macnee W. Cardiovascular Risk in Chronic Obstructive Pulmonary Disease. Respirology. 2007 Sep; 12(5):634-41. PMID: 17875049
20. Choudhury G, Rabinovich R, MacNee W. Comorbidities and Systemic Effects of Chronic Obstructive Pulmonary Disease. Clin Chest Med. 2014 Mar; 35(1):101-30. doi: 10.1016/j.ccm.2013.10.007 PMID: 24507840
21. Fu JJ, McDonald VM, Gibson PG, Simpson JL. Systemic Inflammation in Older Adults with Asthma-Copd Overlap Syndrome. Allergy, Asthma and Immunology Research. 2014 July; 6(4):316-24. doi: 10.4168/aair.2014.6.4.316 PMID: 24991455
22. Sinden NJ, Stockley RA. Systemic Inflammation and Comorbidity in Copd: A Result of 'Overspill' of Inflammatory Mediators from the Lungs? Review of the Evidence. Thorax. 2010 Oct; 65(10):930-6. doi: 10.1136/thx.2009.130260 PMID: 20627907
23. Agusti A. Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should). Proc Am Thorac Soc. 2007 Oct 1; 4(7):522-5. PMID: 17878464
24. Miller J, Edwards LD, Agusti A, Bakke P, Calverley PM, Celli B, et al. Comorbidity, Systemic Inflammation and Outcomes in the Eclipse Cohort. Respir Med. 2013 Sep; 107(9):1376-84. doi: 10.1016/j.rmed.2013.05.001 PMID: 23791463
25. Barabasi AL, Gulbahce N, Loscalzo J. Network Medicine: A Network-Based Approach to Human Disease. Nat Rev Genet. 2011 Jan; 12(1):56-68. doi: 10.1038/nrg2918 PMID: 21164525
26. Grosdidier S, Ferrer A, Faner R, Pinero J, Roca J, Cosio B, et al. Network Medicine Analysis of Copd Multimorbidities. Respir Res. 2014 Sep 24; 15(1):111. doi: 10.1186/s12931-014-0111-4 PMID: 25248857
27. Park J, Lee DS, Christakis NA, Barabasi AL. The Impact of Cellular Networks on Disease Comorbidity. Mol Syst Biol. 2009; 5:262. doi: 10.1038/msb.2009.16 PMID: 19357641
28. Loscalzo J, Barabasi AL. Systems Biology and the Future of Medicine. Wiley Interdiscip Rev Syst Biol Med. 2011 Nov-Dec; 3(6):619-27. doi: 10.1002/wsbm.144 PMID: 21928407
29. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The Hallmarks of Aging. Cell. 2013 Jun 6; 153(6):1194-217. doi: 10.1016/j.cell.2013.05.039 PMID: 23746838
30. Divo MJ, Martinez CH, Mannino DM. Ageing and the Epidemiology of Multimorbidity. Eur Respir J. 2014 Oct; 44(4):1055-68. doi: 10.1183/09031936.00059814 PMID: 25142482
31. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. Epidemiology of Multimorbidity and Implications for Health Care, Research, and Medical Education: A Cross-Sectional Study. Lancet. 2012 Jul 7; 380(9836):37-43. doi: 10.1016/S0140-6736(12)60240-2 PMID: 22579043
32. van den Akker M, Buntinx F, Knottnerus JA. Comorbidity or Multimorbidity. European Journal of General Practice. 1996; 2(2):65-70.
33. Faner R, Cruz T, Lopez-Giraldo A, Agusti A. Network Medicine, Multimorbidity and the Lung in the Elderly. Eur Respir J. 2014 Sep; 44(3):775-88. doi: 10.1183/09031936.00078714 PMID: 25063242
34. Rizzo JA, Chen J, Gunnarsson CL, Naim A, Lofland JH. Adjusting for Comorbidities in Cost of Illness Studies. J Med Econ. 2014 Oct 9:1-17.
35. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. J Chronic Dis. 1987; 40(5):373-83. PMID: 3558716
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a Clinical Comorbidity Index for Use with Icd-9-Cm Administrative Databases. J Clin Epidemiol. 1992 Jun; 45(6):613-9. PMID: 1607900
37. Organisation for Economic Co-operation and Development. Consumer Price Indices (Mei). 2014 Available: http://stats.oecd.org/index.aspx?queryid=221#.
38. Organisation for Economic Co-operation and Development. Purchase Power Parities. 2014; Available: http://stats.oecd.org/Index.aspx?DataSetCode=PPPGDP#.
39. United States Department of Labor. Cpi Inflation Calculator. 2014; Available: http://www.bls.gov/data/inflation-calculator.htm.
40. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (Cheers) Statement. Pharmacoeconomics. 2013 May; 31 (5):361-7. doi: 10.1007/s40273-013-0032-y PMID: 23529207
41. McKeage K, Lyseng-Williamson KA. Trastuzumab: A Pharmacoeconomic Review of Its Use in Early Breast Cancer. Pharmacoeconomics. 2008; 26(8):699-719. PMID: 18620462
42. Molinier L, Bauvin E, Combescure C, Castelli C, Rebillard X, Soulie M, et al. Methodological Considerations in Cost of Prostate Cancer Studies: A Systematic Review. Value Health. 2008 Sep-Oct; 11 (5):878-85. doi: 10.1111/j.1524-4733.2008.00327.x PMID: 18494749
43. Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and Economic Burden of Patients Diagnosed with Copd with Comorbid Cardiovascular Disease. Respir Med. 2011 Oct; 105(10):1516-22. doi: 10.1016/j.rmed.2011.04.005 PMID: 21684731
44. Halpern MT, Zilberberg MD, Schmier JK, Lau EC, Shorr AF. Anemia, Costs and Mortality in Chronic Obstructive Pulmonary Disease. Cost Effectiveness and Resource Allocation. 2006 16 Oct; 4(17).
45. Lin J, Li Y, Tian H, Goodman MJ, Gabriel S, Nazareth T, et al. Costs and Health Care Resource Utilization among Chronic Obstructive Pulmonary Disease Patients with Newly Acquired Pneumonia. Clinicoecon Outcomes Res. 2014; 6:349-56. doi: 10.2147/CEOR.S65824 PMID: 25075195
46. Lin PJ, Shaya FT, Scharf SM. Economic Implications of Comorbid Conditions among Medicaid Beneficiaries with Copd. Respir Med. 2010 May; 104(5):697-704. doi: 10.1016/j.rmed.2009.11.009 PMID: 19954941
47. Polsky D, Bonafede M, Suaya JA. Comorbidities as a Driver of the Excess Costs of Community-Acquired Pneumonia in U.S. Commercially-Insured Working Age Adults. BMC Health Serv Res. 2012; 12:379. doi: 10.1186/1472-6963-12-379 PMID: 23113880
48. Ryan M, Suaya JA, Chapman JD, Stason WB, Shepard DS, Thomas CP. Incidence and Cost of Pneumonia in Older Adults with Copd in the United States. PLoS One. 2013; 8(10):e75887. doi: 10.1371/journal.pone.0075887 PMID: 24130749
49. Shaya FT, Lin PJ, Aljawadi MH, Scharf SM. Elevated Economic Burden in Obstructive Lung Disease Patients with Concomitant Sleep Apnea Syndrome. Sleep Breath. 2009 Nov; 13(4):317-23. doi: 10.1007/s11325-009-0266-2 PMID: 19484281
50. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The Costs of Treating Copd in the United States. Chest. 2001 Feb; 119(2):344-52. PMID: 11171708
51. Menn P, Heinrich J, Huber RM, Jorres RA, John J, Karrasch S, et al. Direct Medical Costs of Copd - an Excess Cost Approach Based on Two Population-Based Studies. Respir Med. 2012 Apr; 106(4):540-8. doi: 10.1016/j.rmed.2011.10.013 PMID: 22100535
52. Dal Negro R, Rossi A, Cerveri I. The Burden of Copd in Italy: Results from the Confronting Copd Survey. Respiratory Medicine. 2003 01 Mar; 97(SUPPL. C):S43-S50. PMID: 12647942
53. Simon-Tuval T, Scharf SM, Maimon N, Bernhard-Scharf BJ, Reuveni H, Tarasiuk A. Determinants of Elevated Healthcare Utilization in Patients with Copd. Respir Res. 2011; 12:7. doi: 10.1186/1465-9921-12-7 PMID: 21232087
54. de Miguel-DiezJ Carrasco-GarridoP Rejas-GutierrezJ Martin-CentenoA Gobartt-VazquezE Her-nandez- BarreraVet alThe Influence of Heart Disease on Characteristics, Quality of Life, Use of Health Resources, and Costs of Copd in Primary Care SettingsBMC Cardiovasc Disord.201010810.1186/1471-2261-10-8PMID: 20167091
55. Thornton Snider J, Luna Y, Wong KS, Zhang J, Chen SS, Gless PJ, et al. Inhaled Corticosteroids and the Risk of Pneumonia in Medicare Patients with Copd. Curr Med Res Opin. 2012 Dec; 28(12):1959-67. doi: 10.1185/03007995.2012.743459 PMID: 23098081
56. Babu KS, Kastelik JA, Morjaria JB. Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: A Pro-Con Perspective. Br J Clin Pharmacol. 2014 Aug; 78(2):282-300. doi: 10.1111/bcp.12334 PMID: 25099256
57. Sin DD, Lacy P, York E, Man SF. Effects of Fluticasone on Systemic Markers of Inflammation in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2004 Oct 1; 170(7):760-5. PMID: 15229100
58. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-Ageing and Lifelong Antigenic Load as Major Determinants of Ageing Rate and Longevity. FEBS Lett. 2005 Apr 11; 579(10):2035-9. PMID: 15811314
59. Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent Systemic Inflammation Is Associated with Poor Clinical Outcomes in Copd: A Novel Phenotype. PLoS One. 2012; 7(5):e37483. doi: 10.1371/journal.pone.0037483 PMID: 22624038
60. Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P. Inhaled Corticosteroids and Pneumonia in Chronic Obstructive Pulmonary Disease. Lancet Respir Med. 2014 Sep 17.
61. Mullerova H, Chigbo C, Hagan GW, Woodhead MA, Miravitlles M, Davis KJ, et al. The Natural History of Community-Acquired Pneumonia in Copd Patients: A Population Database Analysis. Respir Med. 2012 Aug; 106(8):1124-33. doi: 10.1016/j.rmed.2012.04.008 PMID: 22621820
62. Benson MK, Berrill WT, Cruickshank JM, Sterling GS. A Comparison of Four Beta-Adrenoceptor Antagonists in Patients with Asthma. Br J Clin Pharmacol. 1978 May; 5(5):415-9. PMID: 26371
63. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-Use of Beta-Blockers in Patients with Ischaemic Heart Disease and Concomitant Chronic Obstructive Pulmonary Disease. Qjm. 2005 Jul; 98 (7):493-7. PMID: 15955798
64. Kargin F, Takir HB, Salturk C, Goksenoglu NC, Karabay CY, Mocin OY, et al. The Safety of Beta-Blocker Use in Chronic Obstructive Pulmonary Disease Patients with Respiratory Failure in the Intensive Care Unit. Multidiscip Respir Med. 2014; 9(1):8. doi: 10.1186/2049-6958-9-8 PMID: 24495706
65. Lee DS, Markwardt S, McAvay GJ, Gross CP, Goeres LM, Han L, et al. Effect of Beta-Blockers on Cardiac and Pulmonary Events and Death in Older Adults with Cardiovascular Disease and Chronic Obstructive Pulmonary Disease. Med Care. 2014 Mar; 52 Suppl 3:S45-51. doi: 10.1097/MLR.0000000000000035 PMID: 24561758
66. Minor DS, Meyer AM, Long RC, Butler KR. Beta-Blockers and Chronic Obstructive Pulmonary Disease: Inappropriate Avoidance? Journal of Clinical Hypertension. 2013 December; 15(12):925-30. doi: 10.1111/jch.12204 PMID: 24102872
67. Zeng LH, Hu YX, Liu L, Zhang M, Cui H. Impact of Beta2-Agonists, Beta-Blockers, and Their Combination on Cardiac Function in Elderly Male Patients with Chronic Obstructive Pulmonary Disease. Clin Interv Aging. 2013; 8:1157-65. doi: 10.2147/CIA.S49644 PMID: 24072964
68. Puente-Maestu L, Calle M, Ortega-Gonzalez A, Fuster A, Gonzalez C, Marquez-Martin E, et al. Multicentric Study on the Beta-Blocker Use and Relation with Exacerbations in Copd. Respir Med. 2014 May; 108(5):737-44. doi: 10.1016/j.rmed.2014.02.009 PMID: 24635914
69. From the Global Strategy for the Diagnosis, Management and Prevention of Copd, Global Initiative for Chronic Obstructive Lung Disease (Gold) 2014.
70. Black-Shinn JL, Kinney GL, Wise AL, Regan EA, Make B, Krantz MJ, et al. Cardiovascular Disease Is Associated with Copd Severity and Reduced Functional Status and Quality of Life. Copd. 2014 May 15.
71. Mirrakhimov AE. Chronic Obstructive Pulmonary Disease and Glucose Metabolism: A Bitter Sweet Symphony. Cardiovasc Diabetol. 2012; 11:132. doi: 10.1186/1475-2840-11-132 PMID: 23101436
72. Lehnert T, Heider D, Leicht H, Heinrich S, Corrieri S, Luppa M, et al. Review: Health Care Utilization and Costs of Elderly Persons with Multiple Chronic Conditions. Med Care Res Rev. 2011 Aug; 68 (4):387-420. doi: 10.1177/1077558711399580 PMID: 21813576
73. Jansson SA, Backman H, Ronmark E, Lundback B, Lindberg A. Hospitalization Due to Co-Morbid Conditions Is the Main Cost Driver among Subjects with Copd-a Report from the Population-Based Olin Copd Study. Copd. 2014 Nov 21.
74. Lehnert T, Konig HH. [Effects of Multimorbidity on Health Care Utilization and Costs]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 May; 55(5):685-92. doi: 10.1007/s00103-012-1475-6 PMID: 22526857
75. Patel JG, Nagar SP, Dalal AA. Indirect Costs in Chronic Obstructive Pulmonary Disease: A Review of the Economic Burden on Employers and Individuals in the United States. Int J Chron Obstruct Pulmon Dis. 2014; 9:289-300. doi: 10.2147/COPD.S57157 PMID: 24672234
76. Welte R, Feenstra T, Jager H, Leidl R. A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results between Countries. Pharmacoeconomics. 2004; 22(13):857-76. PMID: 15329031
77. Boros PW, Lubinski W. Health State and the Quality of Life in Patients with Chronic Obstructive Pulmonary Disease in Poland: A Study Using the Euroqol-5d Questionnaire. Pol Arch Med Wewn. 2012; 122 (3):73-81. PMID: 22354456
78. Putcha N, Puhan MA, Hansel NN, Drummond MB, Boyd CM. Impact of Co-Morbidities on Self-Rated Health in Self-Reported Copd: An Analysis of Nhanes 2001-2008. Copd. 2013 Jun; 10(3):324-32. doi: 10.3109/15412555.2012.744963 PMID: 23713595
79. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The Human Disease Network. Proc Natl Acad Sci U S A. 2007 May 22; 104(21):8685-90. PMID: 17502601
80. Geppert T, Koeppen H. Biological Networks and Drug Discovery - Where Do We Stand? Drug Dev Res. 2014 Aug; 75(5):271-82. doi: 10.1002/ddr.21207 PMID: 25160067
81. Roukos DH. Genome Network Medicine: Innovation to Overcome Huge Challenges in Cancer Therapy. Wiley Interdiscip Rev Syst Biol Med. 2014 Mar-Apr; 6(2):201-8. doi: 10.1002/wsbm.1254 PMID: 24318985
82. Woodcock J, Griffin JP, Behrman RE. Development of Novel Combination Therapies. N Engl J Med. 2011 Mar 17; 364(11):985-7. doi: 10.1056/NEJMp1101548 PMID: 21323535
83. Levinson AD. Cancer Therapy Reform. Science. 2010 Apr 9; 328(5975):137. doi: 10.1126/science.1189749 PMID: 20378778